flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Semaglutides Are Poised to Remake Chronic Disease Care Kidney Outcomes With Glucagon-Like Peptide-1

Weight Maintenance Experience with GLP-1 class medications demonstrates that weight loss achieved through pharmacotherapy typically requires ongoing medication to maintain

doi: 10.1038/S41598-019-55524-W 116 O'NeilPMBirkenfeldALMcGowanBMosenzonOPedersenSDWhartonSet al

His mission is simple to empower men to look, feel, and perform at their best through science-based therapies that deliver real results

In SURMOUNT-1 (NEJM 2022, 2,539 adults with obesity), the 15 mg arm averaged 22.5% body weight loss at 72 weeks, the 10 mg arm 21.4%, and the 5 mg arm 16.0%

This newer medication was also initially developed for diabetes management and has shown significant potential for weight reduction

This can lead to what is known as adult-onset or age-related growth hormone deficiency